Literature DB >> 29342442

HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab.

Elaine Chang1, Gustavo Rivero2, Niraj R Patel3, Elizabeth Y Chiao4, Syeling Lai5, Kelash Bajaj6, John E Mbue7, Sarvari V Yellapragada2.   

Abstract

Entities:  

Keywords:  Anti-PD-1; Autoimmune diabetes; Human immunodeficiency virus; Immune checkpoint inhibitor; Immune-related adverse event

Mesh：

Substances：

Year:  2018        PMID： 29342442      PMCID： PMC5809264          DOI： 10.1016/j.clml.2017.12.008

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  16 in total

1.  Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Authors:  Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

2.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

Review 3.  PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.

Authors:  Aaron Goodman; Sandip P Patel; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2016-11-02       Impact factor: 66.675

Review 4.  The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.

Authors:  Antonino Carbone; Annunziata Gloghini; Arnaldo Caruso; Paolo De Paoli; Riccardo Dolcetti
Journal:  Int J Cancer       Date:  2016-10-27       Impact factor: 7.396

5.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

6.  HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases.

Authors:  Lester D R Thompson; Stephen I Fisher; Wei Sing Chu; Ann Nelson; Susan L Abbondanzo
Journal:  Am J Clin Pathol       Date:  2004-05       Impact factor: 2.493

7.  Human Immunodeficiency Viruses and Human T-Cell Lymphotropic Viruses.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  1996

Review 8.  HIV-infected cells are frequently clonally expanded after prolonged antiretroviral therapy: implications for HIV persistence.

Authors:  Frank Maldarelli
Journal:  J Virus Erad       Date:  2015-10-01

9.  Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy.

Authors:  Jose D Sandoval-Sus; Francis Mogollon-Duffo; Ankita Patel; Nathan Visweshwar; Damian A Laber; Richard Kim; Michael V Jagal
Journal:  J Immunother Cancer       Date:  2017-06-20       Impact factor: 13.751

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316
View more
  4 in total

Review 1.  Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?

Authors:  Angelos Kyriacou; Eka Melson; Wentin Chen; Punith Kempegowda
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

2.  New-onset insulin-dependent diabetes due to nivolumab.

Authors:  Ali A Zaied; Halis K Akturk; Richard W Joseph; Augustine S Lee
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-03-28

3.  Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab.

Authors:  John A Cuenca; Andres Laserna; María P Reyes; Joseph L Nates; Gregory H Botz
Journal:  Case Rep Crit Care       Date:  2020-03-25

Review 4.  Chemotherapy-Induced Hepatotoxicity in HIV Patients.

Authors:  Silvia Bressan; Alessandra Pierantoni; Saman Sharifi; Sergio Facchini; Vincenzo Quagliarello; Massimiliano Berretta; Monica Montopoli
Journal:  Cells       Date:  2021-10-25       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.